Daily Cardiology Research Analysis
Three impactful cardiology studies span translational mechanisms and clinical device outcomes: bile acid–FXR signaling via taurochenodeoxycholic acid (TCDCA) restores endothelial function in obesity; CTLA-4–Ig (abatacept) preserves post–myocardial infarction function by suppressing T-cell activation; and long-term registry data suggest Absorb bioresorbable scaffolds have early hazards but comparable device outcomes beyond 3 years with lower late myocardial infarction rates versus contemporary DE
Summary
Three impactful cardiology studies span translational mechanisms and clinical device outcomes: bile acid–FXR signaling via taurochenodeoxycholic acid (TCDCA) restores endothelial function in obesity; CTLA-4–Ig (abatacept) preserves post–myocardial infarction function by suppressing T-cell activation; and long-term registry data suggest Absorb bioresorbable scaffolds have early hazards but comparable device outcomes beyond 3 years with lower late myocardial infarction rates versus contemporary DES.
Research Themes
- Endothelial metabolism and bile acid–FXR signaling in obesity
- Immunomodulation after myocardial infarction (T-cell co-stimulation blockade)
- Long-term outcomes and vascular restoration with bioresorbable scaffolds
Selected Articles
1. Taurochenodeoxycholic acid alleviates obesity-induced endothelial dysfunction.
In omental arterioles from 213 non-hypertensive obese individuals, serum bile acids—especially chenodeoxycholic acid—were inversely associated with endothelial dysfunction. Taurochenodeoxycholic acid protected against obesity-induced endothelial dysfunction and hypertension via endothelial FXR activation and a PHB1–ATF4–driven boost in serine/one‑carbon metabolism; endothelial FXR deletion abolished benefits of bariatric surgery or TCDCA.
Impact: This study identifies a mechanistic, druggable endothelial pathway (TCDCA–FXR–PHB1–ATF4) linking bile acid signaling to metabolic reprogramming and vascular protection in obesity, with biomarker (CDCA) and therapeutic (TCDCA) implications.
Clinical Implications: CDCA may serve as a biomarker to identify obesity-related endothelial dysfunction, and TCDCA or endothelial FXR agonism could be explored as therapeutic strategies to delay hypertension and CVD; translation will require early-phase clinical trials and safety assessments.
Key Findings
- Serum bile acids, especially chenodeoxycholic acid, inversely correlated with endothelial dysfunction in 213 non-hypertensive obese patients.
- Taurochenodeoxycholic acid protected against obesity-induced endothelial dysfunction and hypertension.
- Endothelial FXR deletion worsened endothelial dysfunction and abrogated benefits of bariatric surgery or TCDCA.
- Mechanism: TCDCA–FXR activation elevates ATF4 (suppressed by PHB1), enhancing serine/one‑carbon metabolism to restore endothelial function.
Methodological Strengths
- Multisystem translational design combining human ex vivo arterioles, targeted serum metabolomics, and in vivo genetic models.
- Mechanistic validation via endothelial FXR deletion and pathway interrogation (PHB1–ATF4, serine/one‑carbon metabolism).
Limitations
- Human component is cross-sectional; causal inference for serum bile acids and endothelial dysfunction is limited.
- No human interventional trial data for TCDCA; safety, dosing, and off‑target effects remain unknown.
Future Directions: First-in-human dose-finding and mechanistic biomarker trials of TCDCA/FXR agonists in obesity-related endothelial dysfunction; prospective validation of CDCA as a predictive biomarker.
BACKGROUND AND AIMS: Obesity is a global health challenge significantly increasing cardiovascular disease (CVD) burden. Effective prevention and treatment necessitate targeting early pathological changes, particularly obesity-induced endothelial dysfunction (ED). This study aimed to characterize ED heterogeneity in non-hypertensive obese (NHO) individuals, investigate the association of serum metabolites with obesity-induced ED, and identify potentially predictive and therapeutic metabolites. METHODS: Utilizing wire myograph, this study assessed ED of ex vivo arterioles from omental adipose tissue of 213 NHO patients, categorized into metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). Targeted metabolomic profiling identified associations between serum metabolites and ED. RESULTS: Obesity-induced ED in NHO patients lacked correlations with many traditional cardiovascular risk factors. The MHO and MUO individuals exhibited similar ED and metabolomic profile characteristics. Serum metabolomics identified bile acids (BAs), particularly chenodeoxycholic acid (CDCA), as negatively correlated with ED in NHO patients. Taurochenodeoxycholic acid (TCDCA), a taurine-conjugated derivative of CDCA, protected against obesity-induced ED and hypertension. Mechanistically, endothelial Farnesoid X receptor (FXR) deletion aggravated obesity-induced ED and hypertension, negating the beneficial effects of bariatric surgery or TCDCA treatment. The TCDCA-FXR activation in endothelial cells upregulated ATF4 transcription, which was suppressed by PHB1, thereby enhancing serine and one-carbon metabolism. CONCLUSIONS: This study suggests CDCA as a promising biomarker for identification of obesity-induced ED. Taurochenodeoxycholic acid demonstrates significant therapeutic potential for alleviating various forms of obesity-induced ED. This effect is mediated by the endothelial TCDCA-FXR-PHB1-ATF4 axis, which upregulates serine and one-carbon metabolism, thereby offering a novel strategy to delay the onset of hypertension and other CVDs.
2. CTLA-4-Ig therapy preserves cardiac function following myocardial infarction with reperfusion.
In a mouse reperfusion MI model, abatacept (CTLA-4–Ig) suppressed cardiac T-cell activation, reduced innate immune infiltration, and significantly preserved echocardiographic function; benefit persisted even with 24-hour delayed dosing, implying a major T-cell–dependent component of functional loss after MI.
Impact: Defines T-cell co-stimulation as a central, druggable driver of post-reperfusion injury and repurposes an approved immunotherapy (abatacept) with favorable translational potential.
Clinical Implications: Supports clinical exploration of transient, early T-cell co-stimulation blockade after reperfused MI to preserve function; careful safety evaluation is needed to balance infection risk and healing.
Key Findings
- Reperfused MI induced robust, CD4-biased T-cell activation in the heart within 7 days.
- CTLA-4–Ig (abatacept) markedly preserved echocardiographic function and curtailed cardiac T-cell responses and innate immune infiltration.
- Therapeutic benefit remained with dosing delayed up to 24 hours post-MI, indicating a clinically realistic window.
- Mechanistically, >50% of functional loss after reperfusion was T-cell dependent.
Methodological Strengths
- Well-controlled reperfusion model with multimodal readouts (strain echocardiography, flow cytometry).
- Therapeutic window testing with early and delayed dosing regimens increases translational relevance.
Limitations
- Preclinical mouse model; human immunologic responses and safety cannot be inferred.
- No infarct size or scar remodeling endpoints reported; long-term structural outcomes remain unclear.
Future Directions: Phase 1/2 trials of short-course abatacept post-PCI in STEMI/NSTEMI assessing safety, cardiac MRI function/scar, and immune signatures; exploration of optimal timing and duration.
AIMS: T cells drive adverse cardiac inflammation and ischemia-reperfusion injury following myocardial infarction (MI). Here, we aimed to test the extent to which T cell inhibition protected cardiac function following MI in mice. METHODS AND RESULTS: Cardiac ischemia-reperfusion injury (CIRI), mimicking MI with successful reperfusion therapy, was induced in C57BL/6J mice via temporary surgical ligation of the left anterior descending artery. T cell inhibition was achieved using abatacept, an FDA-approved CTLA-4-Ig fusion protein. Multiple treatment strategies were assessed, ranging from prolonged treatment across 4 weeks to short-term treatment, also with delayed time-to-intervention. Cardiac function was assessed using echocardiography, including strain analysis. Impacts on the cardiac and systemic immune response were assessed using flow cytometry. CIRI-induced robust CD4+ biased T cell activation in the heart within 7 days. Treatment with abatacept significantly preserved key echocardiographic metrics of cardiac function. This treatment coincided with near-complete inhibition of the cardiac T cell response, as well as reductions in innate inflammatory cells. Collectively, this demonstrated a central mechanistic role for T cell activation post-MI with reperfusion. Evaluation of short-term intervention strategies further demonstrated sustained preservation of cardiac function even where treatment was delayed by 24 h. Mechanistically, our data indicate that over 50% of lost cardiac function post-MI with reperfusion is T cell dependent. CONCLUSION: T cell co-stimulation leading to activation is a central driver of the cardiac immune response following MI with reperfusion. The inhibition of this axis significantly protected against CIRI and preserved cardiac function. Ultimately, we highlight T cell immunomodulation and abatacept as highly promising approaches for clinical translation.
3. Long-Term Outcome of Percutaneous Coronary Intervention Using Absorb Bioresorbable Scaffold: A SCAAR Study.
In 1,960 propensity-matched patients from the national SCAAR registry, Absorb BRS had higher early device-related events versus DES, but beyond 3 years device outcomes converged and myocardial infarction rates were lower with BRS, supporting a potential late vascular restoration benefit.
Impact: Provides high-quality real-world long-term evidence on BRS: clarifies early hazards versus potential late benefits, informing patient selection and follow-up strategies.
Clinical Implications: Early vigilance for thrombosis/restenosis is warranted after BRS; however, in carefully selected patients, potential late myocardial infarction reductions may justify consideration of vascular restoration strategies.
Key Findings
- Absorb BRS had higher early stent thrombosis, target lesion revascularization, and in-stent restenosis than contemporary DES.
- All-cause mortality and myocardial infarction were similar over overall follow-up.
- Beyond 3 years, device-related outcomes converged, and myocardial infarction rates were lower with Absorb BRS.
- Landmark analysis supports a late benefit consistent with vascular restoration hypothesis.
Methodological Strengths
- Nationwide registry with comprehensive capture and propensity score matching against modern DES.
- Landmark analysis beyond 3 years to assess late device effects.
Limitations
- Observational design with residual confounding despite matching.
- Device iterations and implantation techniques may have evolved over the inclusion period.
Future Directions: Prospective randomized or registry-based randomized trials of next-generation BRS focusing on optimized implantation and long-term vascular restoration endpoints.
BACKGROUND: Bioresorbable scaffolds have been associated with inferior outcomes compared to contemporary permanent metallic drug-eluting stents (DES) for percutaneous coronary intervention, particularly within the initial years after implantation; however, their long-term performance remains uncertain. This study aimed to evaluate the long-term outcomes of Swedish patients treated with Absorb bioresorbable scaffolds (Abbott) vs contemporary DES, assessing device-related complications and examining potential late benefits. The findings seek to clarify the balance between early risks and long-term advantages of bioresorbable scaffolds in clinical practice. METHODS: Complete data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) was used to identify all patients receiving Absorb bioresorbable scaffolds or contemporary DES from November 4, 2011 to March 2, 2018. After 1:2 propensity score matching against modern DES, stent thrombosis, target lesion revascularization, in-stent restenosis, myocardial infarction, and all-cause mortality were analyzed. Landmark analyses were performed from 3 years onward. All patients were followed until January 17, 2022. RESULTS: Among 1960/2406 propensity score matched patients/stents (583/802 Absorb bioresorbable scaffolds and 1377/1604 contemporary DES), bioresorbable scaffolds were associated with significantly higher early stent thrombosis, target lesion revascularization, and in-stent restenosis rates. All-cause mortality and myocardial infarction rates did not differ significantly over the entire follow-up. Beyond 3 years, the device-related outcomes converged, while myocardial infarction rates were lower with Absorb bioresorbable scaffolds than contemporary DES. CONCLUSIONS: Absorb bioresorbable scaffolds showed inferior early clinical performance compared with contemporary DES, but after 3 years, device-related outcomes were similar, while myocardial infarction rates favored Absorb bioresorbable scaffolds. These findings suggest a complex trade-off between early device-related events and potential long-term benefits of bioresorbable scaffold-mediated vascular restoration.